In 2012 BioGaia initiated a double-blind, placebo-controlled study to
investigate the effects of Lactobacillus reuteri Protectis on blood glucose in
type 2 diabetics. Despite positive results from an earlier pilot study no
significant differences between the groups were seen in this study.
Forty-five patients with type 2 diabetes were included in the 12-week long
study. The analysis of the results will continue to capitalise on as much
knowledge as possible.
“There is information in the study that makes us want to go further and analyse
if a change in some of the essential parameters in the study or in the study
design may be a possible approach for a solution”, says Per-Anders Jansson,
Associate Professor and Medical Advisor at Gothia Forum, Sahlgrenska University
Hospital, Gothenburg.
“Unfortunately we did not see any significant differences between the groups,
but given the positive pilot study and the lessons we can draw from the recently
completed study, we intend to continue our work to, with the help of a change of
the microbiome, achieve improvements for patients with type 2 diabetes”, says
Peter Rothschild, President BioGaia.
In the 12-week study 45 patients with type 2 diabetes were included. The study
was conducted together with Gothia Forum for Clinical Research at the
Sahlgrenska University Hospital in Gothenburg in collaboration with Sahlgrenska
Center for Cardiovascular and Metabolic Research.
Latest press releases from BioGaia
2014-01-14 It’s possible to prevent colic in healthy infants
2013-12-05 One of the world’s most widespread infections – BioGaia’s Gastrus
improves treatment
2013-11-15 BioGaia signs exclusive agreement for drops and tablets in Brazil
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 28 January 2014, 3:00
pm CET.
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
